International Relations

News

Share |

$1.6 million grant for cancer drug programme - Australia

Antibody therapeutics company EvoGenix Limited (ASX:EGX) today announced that it had been offered a grant of $1.66 million to fast track development of its anti-cancer antibody, DMF10.

Read more.

7/5/06